Steven Kory, MD
Psychiatry · Elm Springs, ARNPI 1467489450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $560,950 of the $627,917 with a category attached, or 89.3%. 21 manufacturers reported payments, led by AbbVie at 33.8% of the total. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,391 payments — averaging $451.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$163K
- Otsuka America Pharmaceutical, Inc.$81K
- Supernus Pharmaceuticals, Inc.$70K
- Teva Pharmaceuticals USA, Inc.$38K
- Eisai Inc.$21K
- plus $42K from 15 others
What the payments were for
- Consulting fees$10,4982%
- Speaking & faculty fees$560,95089%
- Travel & lodging$37,1116%
- Food & beverage$19,2063%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 406 | $212,017 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 271 | $163,290 |
| Otsuka America Pharmaceutical, Inc. | 138 | $81,322 |
| Supernus Pharmaceuticals, Inc. | 193 | $70,358 |
| Teva Pharmaceuticals USA, Inc. | 59 | $38,386 |
| Eisai Inc. | 64 | $20,694 |
| Johnson & Johnson | 47 | $10,524 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $9,155 |
| Idorsia Pharmaceuticals US Inc | 14 | $8,652 |
| Sunovion Pharmaceuticals Inc. | 32 | $7,229 |
| Indivior Inc. | 15 | $3,904 |
| Vanda Pharmaceuticals Inc. | 24 | $457 |
| Lundbeck LLC | 26 | $433 |
| Neurocrine Biosciences, Inc. | 18 | $421 |
| Alkermes, Inc. | 11 | $353 |
| Corium, LLC | 18 | $297 |
| Axsome Therapeutics, Inc. | 9 | $289 |
| Braeburn Inc. | 2 | $38 |
| Merck | 2 | $34 |
| Harmony Biosciences LLC | 1 | $34 |
| Alfasigma USA, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$206,424
- CAPLYTA$159,894
- REXULTI$78,953
- QELBREE$67,217
- AUSTEDO$23,403
- Dayvigo$20,225
- Austedo XR$12,913
- SPRAVATO$9,403
- TRINTELLIX$8,719
- QUVIVIQ$8,278
- LATUDA$6,699
- PERSERIS$3,679
- LYBALVI$400
- UZEDY$125
- Auvelity$125
- INVEGA SUSTENNA$122
- INVEGA TRINZA$122
- INGREZZA$118
How this compares
$627,917 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 17 | $24,858 |
| Bupropion XlBupropion Hcl | 19 | $744 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $633 |
| Mirtazapine | 27 | $465 |
| Buspirone Hcl | 21 | $362 |
| Propranolol Hcl | 13 | $272 |
| Trazodone Hcl | 21 | $244 |
| Gabapentin | 11 | $243 |
| Escitalopram Oxalate | 18 | $175 |
| Clonazepam | 23 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $212,017 | $24,85817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Elm Springs
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Ronald WautersSearcy$204K
- Herman ClementsSearcy$187K
- Randal ScholmaLowell$111K
- Kyle JohnsonMorrilton$69K
- Paul WylieLittle Rock$54K
- Angela ChapmanFayetteville$40K
- Joann KirchnerNorth Little Rock$39K
- Margaret WeissLittle Rock$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.